MX2020002501A - Formulaciones de nanoparticulas lipidas de vectores de adn libres de capsidos, no virales. - Google Patents

Formulaciones de nanoparticulas lipidas de vectores de adn libres de capsidos, no virales.

Info

Publication number
MX2020002501A
MX2020002501A MX2020002501A MX2020002501A MX2020002501A MX 2020002501 A MX2020002501 A MX 2020002501A MX 2020002501 A MX2020002501 A MX 2020002501A MX 2020002501 A MX2020002501 A MX 2020002501A MX 2020002501 A MX2020002501 A MX 2020002501A
Authority
MX
Mexico
Prior art keywords
capsid
viral
free dna
dna vectors
lipid nanoparticle
Prior art date
Application number
MX2020002501A
Other languages
English (en)
Inventor
Robert Michael Kotin
Ozan Alkan
Douglas Anthony Kerr
Ara Karl Malakian
Matthew John Simmons
Teresa L Wright
Matthew G Stanton
Jie Su
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of MX2020002501A publication Critical patent/MX2020002501A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Botany (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a formulaciones de nanopartículas lípidas que comprenden un lípido ionizable y vectores de ADN libre de cápsido, no virales, con extremos covalentemente cerrados.
MX2020002501A 2017-09-08 2018-09-07 Formulaciones de nanoparticulas lipidas de vectores de adn libres de capsidos, no virales. MX2020002501A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762556333P 2017-09-08 2017-09-08
US201762556334P 2017-09-08 2017-09-08
US201762556381P 2017-09-09 2017-09-09
US201862675327P 2018-05-23 2018-05-23
US201862675322P 2018-05-23 2018-05-23
US201862675324P 2018-05-23 2018-05-23
US201862675317P 2018-05-23 2018-05-23
PCT/US2018/050042 WO2019051289A1 (en) 2017-09-08 2018-09-07 FORMULATIONS OF LIPID NANOPARTICLES OF NON-VIRAL CAPSID-FREE DNA VECTORS

Publications (1)

Publication Number Publication Date
MX2020002501A true MX2020002501A (es) 2020-09-17

Family

ID=65635269

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002501A MX2020002501A (es) 2017-09-08 2018-09-07 Formulaciones de nanoparticulas lipidas de vectores de adn libres de capsidos, no virales.

Country Status (15)

Country Link
US (1) US20210059953A1 (es)
EP (1) EP3679148A4 (es)
JP (2) JP2020537493A (es)
KR (1) KR102696307B1 (es)
CN (1) CN111295448A (es)
AU (1) AU2018330208A1 (es)
BR (1) BR112020004219A2 (es)
CA (1) CA3075180A1 (es)
CO (1) CO2020002262A2 (es)
IL (1) IL272799A (es)
MA (1) MA50096A (es)
MX (1) MX2020002501A (es)
PH (1) PH12020500466A1 (es)
SG (1) SG11202000765PA (es)
WO (1) WO2019051289A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200120649A (ko) * 2018-02-14 2020-10-21 제너레이션 바이오 컴퍼니 비-바이러스 dna 벡터 및 항체 및 융합 단백질 생산을 위한 이의 용도
US20210346306A1 (en) * 2018-05-23 2021-11-11 Modernatx, Inc. Delivery of dna
CN114423869A (zh) 2019-07-19 2022-04-29 旗舰先锋创新Vi有限责任公司 重组酶组合物和使用方法
EP4013879A4 (en) * 2019-08-12 2023-09-13 Generation Bio Co. METHODS AND COMPOSITIONS FOR REDUCING GENETIC OR NUCLEIC ACID THERAPY-RELATED IMMUNE RESPONSE
WO2021046265A1 (en) 2019-09-06 2021-03-11 Generation Bio Co. Lipid nanoparticle compositions comprising closed-ended dna and cleavable lipids and methods of use thereof
BR112022007481A2 (pt) * 2019-11-22 2022-07-12 Generation Bio Co Lipídios ionizáveis e composições de nanopartículas dos mesmos
CN110974954B (zh) * 2019-12-24 2021-03-16 珠海丽凡达生物技术有限公司 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法
TW202208629A (zh) 2020-05-20 2022-03-01 美商旗艦先鋒創新有限責任公司 免疫原性組成物及其用途
WO2021236980A1 (en) 2020-05-20 2021-11-25 Flagship Pioneering Innovations Vi, Llc Coronavirus antigen compositions and their uses
US20230203510A1 (en) 2020-05-29 2023-06-29 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods relating thereto
WO2021243301A2 (en) 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc. Trem compositions and methods relating thereto
EP4189098A1 (en) 2020-07-27 2023-06-07 Anjarium Biosciences AG Compositions of dna molecules, methods of making therefor, and methods of use thereof
AU2021336976A1 (en) 2020-09-03 2023-03-23 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
GB202014751D0 (en) 2020-09-18 2020-11-04 Lightbio Ltd Targeting vector
EP4251170A1 (en) 2020-11-25 2023-10-04 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
WO2022140702A1 (en) 2020-12-23 2022-06-30 Flagship Pioneering, Inc. Compositions of modified trems and uses thereof
WO2022155195A1 (en) * 2021-01-12 2022-07-21 Peranteau William Ionizable lipid nanoparticles for in utero mrna delivery
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
WO2023009547A1 (en) 2021-07-26 2023-02-02 Flagship Pioneering Innovations Vi, Llc Trem compositions and uses thereof
EP4124348A1 (en) * 2021-07-30 2023-02-01 4basebio UK Ltd Nanoparticles for cell delivery
CN118234867A (zh) 2021-09-17 2024-06-21 旗舰创业创新六公司 用于产生环状多核糖核苷酸的组合物和方法
CN118382705A (zh) 2021-10-18 2024-07-23 旗舰创业创新六公司 用于纯化多核糖核苷酸的组合物和方法
AU2022397292A1 (en) 2021-11-24 2024-05-30 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
AU2022397300A1 (en) 2021-11-24 2024-06-27 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and their uses
AU2022398478A1 (en) 2021-11-24 2024-06-13 Flagship Pioneering Innovations Vi, Llc Coronavirus immunogen compositions and their uses
CN118510896A (zh) 2021-12-17 2024-08-16 旗舰创业创新六公司 用于在变性条件下富集环状rna的方法
TW202340461A (zh) 2021-12-22 2023-10-16 美商旗艦先鋒創新有限責任公司 用於純化多核糖核苷酸之組成物和方法
TW202342064A (zh) 2021-12-23 2023-11-01 美商旗艦先鋒創新有限責任公司 編碼抗融合多肽之環狀多核糖核苷酸
WO2023148303A1 (de) * 2022-02-02 2023-08-10 Mslsolutions Gmbh Verfahren zur medikament- und impfstoffherstellung
WO2023177655A1 (en) * 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
WO2023183616A1 (en) 2022-03-25 2023-09-28 Senda Biosciences, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
AR128960A1 (es) * 2022-04-04 2024-06-26 Spark Therapeutics Inc Mejoramiento inmunológico y tratamiento de enfermedades infecciosas
WO2023196634A2 (en) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2023220083A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
WO2023220729A2 (en) 2022-05-13 2023-11-16 Flagship Pioneering Innovations Vii, Llc Double stranded dna compositions and related methods
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2023250112A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
WO2024015428A1 (en) * 2022-07-12 2024-01-18 Trustees Of Boston University Synthetic cellular signaling pathways and uses thereof
WO2024030856A2 (en) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
KR102544632B1 (ko) * 2022-08-05 2023-06-16 주식회사 무진메디 장쇄 세라마이드가 포함된 지질 나노입자 및 이를 포함하는 세포 사멸용 조성물
WO2024035952A1 (en) 2022-08-12 2024-02-15 Remix Therapeutics Inc. Methods and compositions for modulating splicing at alternative splice sites
WO2024049979A2 (en) 2022-08-31 2024-03-07 Senda Biosciences, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024097664A1 (en) 2022-10-31 2024-05-10 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
WO2024102799A1 (en) 2022-11-08 2024-05-16 Flagship Pioneering Innovations Vi, Llc Compositions and methods for producing circular polyribonucleotides
WO2024129988A1 (en) 2022-12-14 2024-06-20 Flagship Pioneering Innovations Vii, Llc Compositions and methods for delivery of therapeutic agents to bone
US20240238473A1 (en) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing
WO2024151583A2 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024151685A1 (en) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing
US20240269263A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
US20240293318A1 (en) 2023-02-13 2024-09-05 Flagship Pioneering Innovations Vii, Llc Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions
US20240293582A1 (en) 2023-02-17 2024-09-05 Flagship Pioneering Innovations Vii, Llc Dna compositions comprising modified cytosine
US20240285805A1 (en) 2023-02-17 2024-08-29 Flagship Pioneering Innovations Vii, Llc Dna compositions comprising modified uracil
WO2024182707A1 (en) 2023-03-02 2024-09-06 Krystal Biotech, Inc. Interleukin-2 and interleukin-12 for cancer therapy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) * 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5869305A (en) * 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
DE10044384A1 (de) * 2000-09-08 2002-04-18 Medigene Ag Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung
US20070004040A1 (en) * 2005-01-06 2007-01-04 Brashears Sarah J RNAi agents for maintenance of stem cells
SI2816118T1 (sl) 2005-05-31 2019-01-31 The Regents Of The University Of Colorado, A Body Corporate Metode za dostavo genov
US9150882B2 (en) * 2006-01-31 2015-10-06 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
AU2016203992A1 (en) * 2009-05-11 2016-06-30 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
EP2500434A1 (en) * 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
AU2013281328B2 (en) * 2012-06-27 2017-11-23 Meiragtx Uk Ii Limited Combination for treating an inflammatory disorder
CA2891911C (en) * 2012-12-07 2023-03-07 Alnylam Pharmaceuticals, Inc. Improved nucleic acid lipid particle formulations
UA117008C2 (uk) * 2013-03-14 2018-06-11 Шир Хьюман Дженетік Терапіс, Інк. IN VITRO ТРАНСКРИБОВАНА мРНК ТА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ, ДЛЯ ЗАСТОСУВАННЯ В ЛІКУВАННІ МУКОВІСЦИДОЗУ В ССАВЦЯ
CA2917018A1 (en) * 2013-05-21 2014-12-04 University Of Florida Research Foundation, Inc. Capsid-modified, raav3 vector compositions and methods of use in gene therapy of human liver cancer
EP4019506A1 (en) * 2013-12-19 2022-06-29 Novartis AG Lipids and lipid compositions for the delivery of active agents
EP3242945B1 (en) * 2015-01-07 2021-09-01 Universitat Autònoma de Barcelona Single-vector gene construct comprising insulin and glucokinase genes
CA3021949C (en) * 2015-04-24 2023-10-17 University Of Massachusetts Modified aav constructs and uses thereof
JP7114465B2 (ja) * 2015-12-22 2022-08-08 モデルナティエックス インコーポレイテッド 薬剤の細胞内送達のための化合物および組成物
AU2017228413A1 (en) * 2016-03-03 2018-08-23 University Of Massachusetts Closed-ended linear duplex DNA for non-viral gene transfer

Also Published As

Publication number Publication date
CA3075180A1 (en) 2019-03-14
WO2019051289A9 (en) 2019-05-23
PH12020500466A1 (en) 2021-01-25
IL272799A (en) 2020-04-30
US20210059953A1 (en) 2021-03-04
KR20200051708A (ko) 2020-05-13
SG11202000765PA (en) 2020-03-30
AU2018330208A1 (en) 2020-02-27
CN111295448A (zh) 2020-06-16
EP3679148A4 (en) 2021-06-09
BR112020004219A2 (pt) 2020-09-08
JP2020537493A (ja) 2020-12-24
RU2020110805A3 (es) 2022-01-19
KR102696307B1 (ko) 2024-08-16
CO2020002262A2 (es) 2020-05-29
RU2020110805A (ru) 2021-10-11
JP2023002828A (ja) 2023-01-10
EP3679148A1 (en) 2020-07-15
WO2019051289A1 (en) 2019-03-14
MA50096A (fr) 2020-07-15

Similar Documents

Publication Publication Date Title
PH12020500466A1 (en) Lipid nanoparticle formulations of non-viral, capsid-free dna vectors
SG10202011219YA (en) Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
SA520411636B1 (ar) صيغ جسيمات نانوية دهنية
MY194032A (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
PH12018502645A1 (en) Optimized mini-dystrophin genes and expression cassettes and their use
SG11202003754YA (en) High concentration protein formulations with reduced viscosity
CY1120373T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
MX2023004479A (es) Sistema de vector multiple y sus usos.
MX2020003596A (es) Composiciones de acido nucleico-polipeptido y usos de las mismos.
MX2018009750A (es) Composiciones potenciadoras de vcn y métodos para su uso.
PH12018500568A1 (en) Antisense nucleic acid
EP4219532A3 (en) Compositions and methods for transient gene therapy with enhanced stability
MX2018002106A (es) Vacunas terapeuticas contra el hpv18.
MX2017016400A (es) Vectores para uso en un sistema de coexpresion inducible.
MA40902B1 (fr) Vaccins hpv16 thérapeutiques
EP3615079A4 (en) STABLE CANNABINOID FORMULATIONS
EP3462885A4 (en) STABLE CANNABINOID FORMULATIONS
EP3595629A4 (en) NONVIRAL, NONCATIONIC NANOPARTICLE AND USES THEREOF
EP3454908A4 (en) TARGETED CONSTRUCTS AND FORMULATIONS THEREOF
SA519401756B1 (ar) أجزاء منشأة للتعبير الوراثي عن رنح فريدريك
MX2021006674A (es) Composiciones para estabilizar bacterias y usos de las mismas.
EP3246406A4 (en) Gene expression system using stealthy rna, and gene introduction/expression vector including said rna
IL268515A (en) Evolocumab formulations with high concentration and low viscosity and methods for their preparation
WO2018183692A8 (en) VECTORS AND COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
IL287435A (en) Stable, low-viscosity antibody formulations and their uses